MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

21st International Congress » Parkinson's Disease: Psychiatric Manifestations

Date: Wednesday, June 7, 2017

Time: 1:15pm-2:45pm

Location: Exhibit Hall C

Meeting: 21st International Congress

1:15pm-2:45pm
Absence of depression in de novo Parkinson’s disease: a benign motor phenotype?

H.S. YOO, Y. Lee, J.J. Lee, S.J. Chung, P.H. Lee, Y.H. Sohn (Seoul, Republic of Korea)

1:15pm-2:45pm
Baseline Clinical Predictors of Future Psychotic Symptoms in de novo Parkinson Disease

M. Barrett, M. Smolkin (Charlottesville, VA, USA)

1:15pm-2:45pm
Behavioral and psychological symptoms in Parkinson’s disease with SWEDDs

J. Ahn, H. Kim (Seoul, Republic of Korea)

1:15pm-2:45pm
Capgras syndrome in advanced Parkinson disease

C. Groth, A. Pusso, D. Huss, S. Sperling, B. Shah, M. Harrison, W.J. Elias, G.F. Wooten, M. Barrett (Charlottesville, VA, USA)

1:15pm-2:45pm
Compulsive sexual behaviour in Parkinson’s disease is associated with higher doses of levodopa

P. Barbosa, T. Warner, A. Djamshidian (London, United Kingdom)

1:15pm-2:45pm
Delusional Misidentification Syndrome for “Self” in two patients with Parkinson`s Disease.

S. Ray, D. Park, D. Burdick, A. Griffith, J. Shaw, P. Agarwal (Kirkland, WA, USA)

1:15pm-2:45pm
Domain-Specific Cognitive Impairment in Non-Demented Parkinson’s Disease Psychosis

J. Hinkle, K. Perepezko, C. Bakker, T. Dawson, V. Johnson, Z. Mari, C. Marvel, K. Mills, A. Pantelyat, O. Pletnikova, L. Rosenthal, M. Shepard, D. Stevens, J. Troncoso, J. Wang, G. Pontone (Baltimore, MD, USA)

1:15pm-2:45pm
Dopamine agonist therapy mediates relationship between psychomotor inhibition and behavioral impulsivity in Parkinson’s disease.

T. Turner, J. Renfroe, V. Hinson (Charleston, SC, USA)

1:15pm-2:45pm
Electrophysiological markers for emotional and cognitive impairment in Parkinson’s disease

N. Dissanayaka, T. Au, A. Angwin, J. O'Sullivan, G. Byrne, P. Silburn, R. Marsh, G. Mellick, D. Copland (Brisbane, Australia)

1:15pm-2:45pm
Genetics of impulse control disorders in Parkinson’s disease: a case control study

J.-C. Corvol, F. Cormier-Dequaire, S. Bekadar, S. Prud'hon, M. Anheim, J.-P. Azulay, F. Durif, J.-L. Houeto, A. Destée, K. Tahiri, G. Mangone, L. Lacomblez, P. Krack, P. Krystkowiak, D. Maltête, O. Rascol, C. Tranchant, M. Vidailhet, A. Brice, S. Tezenas duMontcel (Paris, France)

1:15pm-2:45pm
Improving Diagnosis and Treatment of Anxiety in Parkinson’s Disease: IDATA-PD Study

N. Dissanayaka, N. Pachana, J. O'Sullivan, R. Marsh, P. Silburn, E. White, E. Torbey, D. Pye, L. Mitchell, J.H. Yang, T. Au, G. Mellick, D. Copland, A. Toft, G. Byrne (Brisbane, Australia)

1:15pm-2:45pm
Impulse Control Disorders in Parkinson’s Disease: Prevalence and Clinical Features in the Rush University Movement Disorders Clinic

M. Rossi, G. Stebbins, B. Barton (Chicago, IL, USA)

1:15pm-2:45pm
Longitudinal analysis of the relation of dopamine agonist use with impulse control disorders in Parkinson’s disease

j.-c. corvol, F. Artaud, O. Rascol, F. Durif, P. Derkinderen, F. Bourdain, J.-P. Brandel, f. Pico, L. Lacomblez, C. Bonnet, D. Grabli, S. Klebe, G. Mangone, H. You, v. Mesnage, P.C. Lee, A. Brice, M. Vidailhet, F. Cormier-Dequaire, A. Elbaz (Paris, France)

1:15pm-2:45pm
Minor hallucinations in Parkinson’s disease: neuropshycological and neurophysiological correlates in a representative sample of non-demented patients.

J. Pagonabarraga, J. Marin-Lahoz, A. Horta, H. Bejr-Kasem, M. Cornella, J. Pérez-Pérez, S. Martinez-Horta, J. Kulisevsky (Barcelona, Spain)

1:15pm-2:45pm
Othello syndrome amongst patients with Parkinson’s disease in a rural movement disorders clinic in western India

S. Desai, D. Desai (Anand, India)

1:15pm-2:45pm
Perceptions of Fluctuation Treatment in Parkinson’s Disease Impact Suicidality

J. Hinkle, K. Perepezko, Z. Mari, L. Marsh, G. Pontone (Baltimore, MD, USA)

1:15pm-2:45pm
Predictors of onset of psychosis in Parkinson’s disease: “Who gets it early?”

P. Pal, A. Lenka, L. George, S. Arumugham, S. Hegde, N. Kamble, R. Yadav (Bangalore, India)

1:15pm-2:45pm
Short term effects of bilateral STN DBS on psychiatric profile in Parkinson’s disease

R. Alugolu, M.B. Kesani, B. Ganji, V. Mudumba, R. Mrudula, R. Borgohain, P. Gaddamanugu (Hyderabad, India)

1:15pm-2:45pm
Suicidality in Parkinson’s Disease: A Case Control Study

M. Akbostanci, E. Bayram, D. Sayar, T. Ayidaga (Ankara, Turkey)

1:15pm-2:45pm
Systematic Evaluation of Major and Minor Psychotic Symptoms in Parkinson’s Disease

C. Kulick, K. Montgomery, M. Nirenberg (New York, NY, USA)

1:15pm-2:45pm
The role of habenula and amygdala dysfunction in Parkinson’s disease patients with punding

V. Markovic, F. Agosta, E. Canu, A. Inuggi, I. Petrovic, I. Stankovic, F. Imperiale, T. Stojkovic, V. Kostic, M. Filippi (Belgrade, Serbia)

1:15pm-2:45pm
Treatment of Parkinson’s disease psychosis–a systematic review of RCTs

K. Cook, D. Nellesen, K. Adamski, A. Shim (Menlo Park, CA, USA)

1:15pm-2:45pm
Treatment of Psychosis in Parkinson’s Disease: Evidence-Based Recommendations Versus Actual Clinical Practice

L.G. Chan, A. Kong, L. Tan (Singapore, Singapore)

1:15pm-2:45pm
What do patients with Parkinson’s disease see in their hallucinations? Classification of hallucinations which are seen in Parkinson’s Disease; Single Center Experience

A. Acarer, S. Ciftci, Z. Colakoglu (Izmir, Turkey)

« View all sessions from the 21st International Congress.

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley